Spravato & Ketamine As Treatment Options - Milwaukee
Spectrum Healthcare is working on making this option available to you in our clinic in the near future.
Spravato is a nasal spray containing Esketamine, a type of Ketamine that is FDA approved for severe depression. Ketamine is an FDA-approved as anesthetic medication and has been used for many decades. It has been shown in numerous scientific studies to be effective for acute severe depression but the generic version is currently not FDA approved for depression at this time. Both work to aid the treatment of Treatment-Resistant Depression (TRD) as well as those showing symptoms of Major Depressive Disorder (MDD).
Spravato is a nasal spray that is taken under the supervision of one of our providers at Spectrum Healthcare. It contains a type of Ketamine called Esketamine.
Spravato is taken twice a week for four weeks and then it is taken once a week for another four weeks. After that, one of our providers at Spectrum Healthcare will develop a treatment plan that is best for you.
Each treatment session lasts for about two hours during which you will be monitored by one of our providers. After the drug is taken it will be up to a caregiver or family member to drive you back home safely as you are not allowed to drive until after a good night’s rest. It should also be noted that Spravato is not for everyone, which is why a comprehensive assessment will be done prior to developing a treatment plan.
If you’ve tried two or more antidepressants and are still struggling with depressive symptoms, SPRAVATO may offer relief.
Do you want to learn more about Spravato vs Ketamine medication?
Usually covered by insurance
Most insurance plans cover SPRAVATO when prescribed by a physician. Contact your insurance provider to confirm coverage.
Proven effective in clinical studies
SPRAVATO was studied in adults with treatment-resistant depression.
After four weeks, patients taking SPRAVATO and an oral antidepressant saw a greater reduction of depressive symptoms (compared to those who received a placebo and an oral antidepressant).
After 16 weeks of therapy, those patients who stayed on SPRAVATO, along with an oral antidepressant, did better than those who stopped therapy.